* Alteon Inc., of Ramsey, N.J., appointed to the board of directorsFrank Spiegel, former executive vice president of Merck & Co. Inc.,of Whitehouse Station, N.J.

* Applied Microbiology Inc., of Tarrytown, New York, named thefollowing to the board of directors: Douglas Cotter, president ofMassachusetts-based Healthcare Decisions Inc.; Audrey Cross,associate clinical professor at Columbia University in New York;and Robert Pollack, professor of biological sciences at ColumbiaUniversity.

* Aradigm Corp., of Hayward, Calif., named Stephen Farr directorof pharmaceutical research and development.

* Corvas International Inc., of San Diego, appointed William Ripkasenior vice president of chemical research and George Vlasuk vicepresident of biological research.

* Dianon Systems Inc., of Stratford, Conn., named Richard Sandbergpresident and CEO and appointed Jack Davis, Dianon's formerpresident and CEO, vice chairman of the board of directors.

* Gen-Probe Inc., of San Diego, named Graham Lidgard vicepresident of diagnostic research and development and Larry Mimmsdirector of diagnostic research.

* IMUTEC Corp., of Toronto, named Wayne Cockburn vicepresident of corporate development.

* Micrologix Biotech Inc., of Vancouver, Canada, appointedWilliam Foran, former president and CEO of Vancouver-basedQuadra Logics Technologies, vice chairman of Micrologix's boardof directors.

* MicroProbe Corp., Bothell, Wash., named Sanford Zweifach chieffinancial officer and president or therapeutics.

* Neurobiological Technologies Inc., of Richmond, Calif., namedRonald Goldblum vice president of medical affairs.

* Pharma Mar S.A., of Madrid, Spain, named Michael Rosenpresident and CEO.

* Procept Inc., of Cambridge, Mass., appointed to the board ofdirectors James Cavanaugh, former president of SmithKline andFrench Laboratories, a subsidiary of U.K.-based SmithKlineBeecham plc.

* Rhone-Poulenc Rorer Inc., of Collegeville, Pa., appointed Michelde Rosen CEO effective April 25.

* Targeted Genetics Corp., of Seattle, appointed Richard Daifukuvice president of clinical affairs.


January 30, 1995

Vol. 6, No. 18


cYTOerapeutics Inc., of Providence, R.I., withdrew its proposedfollow-on public offering of 2 million shares, citing poor marketconditions and the company's cash reserves of about $19 million.CytoTherapeutics said it is pursuing alternate financing.

* Gensia Inc., of San Diego, received a product license in Sweden tomarket its GenESA system for diagnosing coronary artery disease inassociation with electrocardiography, echocardiography andradionuclide imaging.

* Martek Biosciences Corp., of Columbia, Md., said it plans to pay$10 million in cash, stock and promissory notes to purchase afermentation facility from Golden Technologies Co. Inc. inWinchester, Ky. The deal is expected to be finalized in March.

* Matritech Inc., of Cambridge, Mass., received a Small BusinessInnovative Research grant from the National Cancer Institute for$88,000. The funds will be used for cloning the gene that expressesPC-1, which has been identified as a prostate cancer-specific nuclearmatrix protein.

* SangStat Medical Corp., of Menlo Park, Calif., began volumemanufacturing of its Transtat product as part of a licensingagreement with Paris-based Diagnostica Stago S.A. Stago is usingTranstat in a diagnostic to test D-Dimer, which is associated withblood coagulation disorders. SangStat is developing Transtat forpost-transplant monitoring.

* Cypros Pharmaceutical Corp., of Carlsbad, Calif., said a Phase Itrial of CPC-211 for cerebral ischemic disorders showed the drugwas well tolerated at three dose levels. Thirty-six healthy volunteersparticipated in the study.

* NaPro BioTherapeutics Inc., of Boulder, Colo., received approvalfrom Australia's Therapeutic Goods Administration to market itsanti-cancer paclitaxel drug, Anzatax, for advanced refractory ovarianand breast cancers. Anzatax will be sold in Australia by NaPro'spartner, F.H. Faulding & Co. Ltd. in South Australia.

* Pharmos Corp., of New York, said its stock (PARS) will be listedon the Nasdaq SmallCap Market, following a decision by the NasdaqListing Qualifications Committee to remove the company from theNasdaq National Market. The move was effective Jan. 27.

* Synsorb Biotech Inc., of Calgary, Alberta, signed an agreementwith the Alberta Heritage Foundation for Medical Research for$387,000 to help fund Synsorb's Phase II/III of Synsorb Pk fortreatment of Hemolytic Uremic Syndrome, also known as hamburgerdisease.

* VIMRx Pharmaceuticals Inc., of Stamford, Conn., purchasedexclusive rights to technology for synthetic nucleic acid-basedcompounds that target messenger RNA, preventing it fromproducing disease-causing proteins. VIMRx declined to disclosefinancial details and did not identify the company selling thetechnology.

* Zonagen Inc., of The Woodlands, Texas, said Pharmaco LSR Inc.,a clinical research organization in Austin, Texas, will conductZonagen's Phase II trials of oral phentolamine for male impotency atmultiple sites in Germany with 160 patients.

(c) 1997 American Health Consultants. All rights reserved.